The Anti-SARS-CoV-2 S-Protein IgG, Which Is Detected Using the Chemiluminescence Microparticle Immunoassay (CMIA) in Individuals Having Either a History of COVID-19 Vaccination and/or SARS-CoV-2 Infection, Showed a High-Titer Neutralizing Effect
Author:
Cin Dilan12ORCID, Soguksu Pinar1, Oren Meryem Merve3ORCID, Ozgulnar Nuray3ORCID, Agacfidan Ali1, Mese Sevim1ORCID
Affiliation:
1. Department of Medical Microbiology, Istanbul Medicine Faculty, Istanbul University, 34093 Istanbul, Turkey 2. Institute of Health Sciences, Istanbul University, 34126 Istanbul, Turkey 3. Department of Public Health, Istanbul Medicine Faculty, Istanbul University, 34093 Istanbul, Turkey
Abstract
Neutralizing antibodies plays a primary role in protective immunity by preventing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) from entering the cells. Therefore, characterization of antiviral immunity is important for protection against SARS-CoV-2. In this study, the neutralizing effect of the anti-SARS-CoV-2 S1 protein IgG, which was detected using the chemiluminescence microparticle immunoassay (CMIA)-based SARS-CoV-2 IgG II Quant (Abbott, Waukegan, IL, USA) test in SARS-CoV-2 infected and/or vaccinated individuals, was investigated with a surrogate virus neutralization test (sVNT). In total, 120 Seropositive individuals were included in this study. They were divided into two groups: Vaccinated (n = 60) and Vaccinated + Previously Infected (n = 60). A commercial sVNT, the ACE2–RBD Neutralization Test (Dia.Pro, Milan, Italy), was used to assess the neutralizing effect. The assay is performed in two steps: screening and titration. The screening showed positive results in all seropositive samples. Low titration in 1.7%, medium titration in 5%, and high titration in 93.3% of the Vaccinated group, and medium titration in 1.7% and high titration in 98.3% of the other group, as obtained from the ACE2-RBD titration test. A strong positive and significant correlation was found between the SARS-CoV-2 IgG II Quant test and the ACE2-RBD titration test at the 1/32 titration level for both groups (p < 0.001 for both). This study shows that the SARS-CoV-2 IgG detected using the CMIA method after SARS-CoV-2 infection and/or vaccination has a high neutralizing titration by using the sVNT. In line with these data, knowledge that seropositivity determined by CMIA also indicates a strong neutralizing effect contributes to countrywide planning for protecting the population.
Funder
Istanbul University Scientific Research Projects Unit
Reference40 articles.
1. Post, N., Eddy, D., Huntley, C., van Schalkwyk, M.C.I., Shrotri, M., Leeman, D., Rigby, S., Williams, S.V., Bermingham, W.H., and Kellam, P. (2020). Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS ONE, 15. 2. Winichakoon, P., Wipasa, J., Chawansuntati, K., Salee, P., Sudjaritruk, T., Yasri, S., Khamwan, C., Peerakam, R., Dankai, D., and Chaiwarith, R. (2023). Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT). Sci. Rep., 13. 3. Antibody and Virus: Binding and Neutralization;Burton;Virology,2000 4. Cavlek, T.V., Stevanovic, V., Kovac, S., Borko, E., Bogdanic, M., Miletic, G., Hruskar, Z., Ferenc, T., Coric, I., and Ferenc, M.V. (2023). Neutralizing Activity of SARS-CoV-2 Antibodies in Patients with COVID-19 and Vaccinated Individuals. Antibodies, 12. 5. Chvatal-Medina, M., Mendez-Cortina, Y., Patino, P.J., Velilla, P.A., and Rugeles, M.T. (2021). Antibody Responses in COVID-19: A Review. Front. Immunol., 12.
|
|